Beckman's latest antibody aids cancer research
identifies Tolereogenic cells making it highly in transplant and
cancer research. It is also applicable in clinical research on
autoimmunity.
The CD85d-PE conjugated monoclonal antibody delivers advantages over other antibodies in applications where control of tolerogenicity is important.
Tolerogenicity refers to the property that allows a substance to induce specific immunologic non-responsiveness in either the humoral or cell-mediated branch. Such substances are termed tolerogens.
In making this antibody available, Beckman Coulter provides a helping hand to not only cancer researchers but also basic research on leucocyte function, dendritic cells, immunosuppression, tolerogenicity and maternofoetal tolerance.
ILT4 is selectively expressed on myelomonocytic cells and binds to classical and nonclassical human leucocyte antigen (HLA) class I molecules.
ILT4 is believed to play a number of roles in cellular function, including the modulation of APC functions (e.g. antigen uptake, migration and cytokine production), control of inflammatory response and maternal tolerance against the foetal semi-allograft.
CD85d-PE is offered exclusively by Beckman Coulter and completes the company's list of clones against immunoglobulin (Ig)-like transcripts.
"We are excited to increase our offerings in ILT markers," said Michel Pagniez, cellular analysis product manager for Beckman Coulter. "The biology of these types of cells is critical to driving immune response."
The preformulated, standardised IOTest CD85d-PE monoclonal antibody is provided in 100-test vials. Beckman Coulter offers a number of reagents, controls and markers that can be used with this new antibody. CD85d-PE is approved for research use only.
For more details of the IOTestR CD85d-(ILT4)-PE conjugated monoclonal antibody, visit >Beckman Coulter's website.
